Summit Therapeutics plc Stock London S.E.
Stocks
GB00BN40HZ01
Biotechnology & Medical Research
| Market Cap | 7.52B 10.2B 8.8B 8.26B 14.14B 975B 14.34B 96.8B 37.93B 488B 38.28B 37.45B 1,625B | P/E 2026 * |
-10.6x | P/E 2027 * | -10.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.05B 9.55B 8.25B 7.74B 13.25B 913B 13.43B 90.7B 35.54B 458B 35.87B 35.09B 1,522B | EV / Sales 2026 * |
2,407x | EV / Sales 2027 * | 175x |
| Free-Float |
19.11% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Summit Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 54 | 25/07/2022 |
Robert Duggan
CEO | Chief Executive Officer | 81 | 01/04/2020 |
| Director of Finance/CFO | 48 | 02/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Duggan
CHM | Chairman | 81 | 01/02/2020 |
| Director/Board Member | 48 | 01/12/2019 | |
Mahkam Zanganeh
BRD | Director/Board Member | 54 | 11/11/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.38% | - | - | 10.65B | |
| +4.80% | +7.80% | +70.64% | +114.21% | 70.07B | |
| +17.12% | +12.05% | +54.42% | +86.20% | 52.87B | |
| +3.70% | -2.12% | +0.41% | +469.55% | 27.02B | |
| +2.26% | +0.65% | +49.19% | +10.30% | 23.61B | |
| -1.60% | -2.21% | -19.31% | -15.15% | 23.38B | |
| -6.00% | +13.71% | +244.39% | +443.26% | 19.43B | |
| +3.80% | +5.25% | +40.50% | -16.41% | 18.75B | |
| +0.38% | -3.15% | +20.39% | +589.77% | 15.85B | |
| +2.11% | -3.24% | +36.57% | +145.40% | 12.7B | |
| Average | +2.66% | -2.08% | +55.25% | +203.01% | 29.3B | |
| Weighted average by Cap. | +4.90% | -1.14% | +56.29% | +169.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 22.38M 30.35M 26.2M 24.58M 42.09M 2.9B 42.67M 288M 113M 1.45B 114M 111M 4.84B |
| Net income | -692M -938M -810M -760M -1.3B -89.72B -1.32B -8.91B -3.49B -44.95B -3.52B -3.45B -150B | -730M -990M -854M -801M -1.37B -94.62B -1.39B -9.4B -3.68B -47.4B -3.72B -3.63B -158B |
| Net Debt | -474M -642M -554M -520M -890M -61.38B -903M -6.1B -2.39B -30.75B -2.41B -2.36B -102B | -202M -274M -237M -222M -380M -26.22B -386M -2.6B -1.02B -13.13B -1.03B -1.01B -43.69B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
